Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 0.63 |
| ▸ | CYP1A1 | P04798 | 5/20 | 0.58 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.58 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PDE5A | O76074 | 1/20 | 0.45 |
| ▸ | PDE9A | O76083 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30632888 | 1.00 | MIF (0.63) | MIFCYP1A1CYP1B1BACE1GAA | |
| SCHEMBL584622 | 1.00 | MIF (0.63) | MIFCYP1A1CYP1B1BACE1GAA | |
| SCHEMBL29462467 | 1.00 | MIF (0.63) | MIFCYP1A1CYP1B1BACE1GAA | |
| Hydrochloric Acid SCHEMBL6821766 | 0.98 | MIF (0.61) | MIFCYP1A1CYP1B1BACE1GAA | |
| SCHEMBL7814628 | 0.87 | BACE1 (0.60) | MIFCYP1A1CYP1B1BACE1GAA | |
| SCHEMBL7814631 | 0.87 | BACE1 (0.60) | MIFCYP1A1CYP1B1BACE1GAA | |
| SCHEMBL30633014 | 0.85 | CYP1A1 (0.57) | MIFCYP1A1CYP1B1BACE1GAA | |
| SCHEMBL6821761 | 0.85 | CYP1A1 (0.57) | MIFCYP1A1CYP1B1BACE1GAA | |
| SCHEMBL29462470 | 0.85 | CYP1A1 (0.57) | MIFCYP1A1CYP1B1BACE1GAA | |
| SCHEMBL4602568 | 0.85 | CYP1A1 (0.57) | MIFCYP1A1CYP1B1BACE1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12286426-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | Université de Montréal (CA) | 2025-04-29 | — | — | US | disclosed |
| EP-3704111-B1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | UNIV MONTREAL (CA) | 2024-10-09 | — | — | EP | disclosed |
| CN-114230519-B | Pleuromutilin cinnamate compounds with drug-resistant bacteria resisting activity, and synthetic method and application thereof | 西咸新区沣厚原创医药科技有限公司 | 2024-06-04 | — | — | CN | disclosed |
| US-11872202-B2 | Pleuromutilin cinnamic acid ester compounds with activities against antibiotic-resistant infections | SHAANXI UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2024-01-16 | — | — | US | disclosed |
| US-20230357221-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | UNIV MONTREAL (CA) | 2023-11-09 | — | — | US | disclosed |
| US-11760754-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | Université de Montréal (CA) | 2023-09-19 | — | — | US | disclosed |
| US-20230172889-A1 | PLEUROMUTILIN CINNAMIC ACID ESTER COMPOUNDS WITH ACTIVITIES AGAINST ANTIBIOTIC-RESISTANT INFECTIONS | SHAANXI UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2023-06-08 | — | — | US | disclosed |
| CN-114230519-A | Pleuromutilin cinnamate compounds with drug-resistant bacterium resisting activity and synthesis method and application thereof | 陕西科技大学 | 2022-03-25 | — | — | CN | disclosed |
| US-20210387980-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | Université de Montréal (CA) | 2021-12-16 | — | — | US | disclosed |
| EP-3704111-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | Université de Montréal (CA) | 2020-09-09 | — | — | EP | disclosed |
| EP-1463714-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2004-10-06 | — | — | EP | disclosed |
| WO-2004046122-A2 | BENZOXAZOLE, BENZTHIAZOLE AND BENZIMIDAZOLE ACID DERIVATIVES AND THEIR USE AS HEPARANASE INHIBITORS | OXFORD GLYCOSCIENCES (UK) LTD (GB) | 2004-06-03 | — | — | WO | disclosed |
| JP-2004149458-A | METHOD FOR PRODUCING FLUORO(TRIFLUOROMETHYL)CINNAMIC ACID | CENTRAL GLASS CO LTD | 2004-05-27 | — | — | JP | disclosed |
| WO-2004039760-A1 | PROCESS FOR PRODUCTION OF FLUORO(TRIFLUOROMETHYL)- CINNAMIC ACID | CENTRAL GLASS COMPANY, LIMITED (JP) | 2004-05-13 | — | — | WO | disclosed |
| US-20030195201-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2003-10-16 | — | — | US | disclosed |
| US-20030195190-A1 | Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes | HIGH POINT PHARMACEUTICALS, LLC | 2003-10-16 | — | — | US | disclosed |
| WO-2003064411-A1 | AMIDES OF AMINOALKYL-SUBSTITUTED AZETIDINES, PYRROLIDINES, PIPERIDINES AND AZEPANES | NOVO NORDISK A/S (DK) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003049702-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2003-06-19 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172889-A1 | PLEUROMUTILIN CINNAMIC ACID ESTER COMPOUNDS WITH ACTIVITIES AGAINST ANTIBIOTIC-RESISTANT INFECTIONS | RELA, PLEC, ABL1 | MIF 5/4885CYP1A1 1574/4885CYP1B1 2173/4885 |
| US-20030195190-A1 | Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes | HRH3, HRH2, HRH4 | MIF 4349/4885CYP1A1 1962/4885CYP1B1 2610/4885 |
| US-20030195201-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | MIF 2023/4885CYP1A1 1906/4885CYP1B1 2275/4885 |
| US-20230357221-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | IDH2, TFAM, IDH1 | MIF 2286/4885CYP1A1 1340/4885CYP1B1 1021/4885 |
| US-11872202-B2 | Pleuromutilin cinnamic acid ester compounds with activities against antibiotic-resistant infections | RELA, PLEC, ABL1 | MIF 5/4885CYP1A1 1574/4885CYP1B1 2173/4885 |
| US-12286426-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | IDH2, TFAM, IDH1 | MIF 2286/4885CYP1A1 1340/4885CYP1B1 1021/4885 |
| US-20210387980-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | IDH2, TFAM, NUTF2 | MIF 2317/4885CYP1A1 1142/4885CYP1B1 915/4885 |
| US-11760754-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | IDH2, TFAM, NUTF2 | MIF 2317/4885CYP1A1 1142/4885CYP1B1 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.